Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP)

BACKGROUND: Simvastatin, 20 mg, plus ezetimibe, 10 mg, daily (simvastatin plus ezetimibe) reduced major atherosclerotic events in patients with moderate to severe chronic kidney disease (CKD) in the Study of Heart and Renal Protection (SHARP), but its cost-effectiveness is unknown. STUDY DESIGN: Cos...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Am J Kidney Dis
Main Authors: Mihaylova, Borislava, Schlackow, Iryna, Herrington, William, Lozano-Kühne, Jingky, Kent, Seamus, Emberson, Jonathan, Reith, Christina, Haynes, Richard, Cass, Alan, Craig, Jonathan, Gray, Alastair, Collins, Rory, Landray, Martin J., Baigent, Colin
Formato: Artigo
Idioma:Inglês
Publicado em: W.B. Saunders 2016
Assuntos:
Original Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4801501/
https://ncbi.nlm.nih.gov/pubmed/26597925
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1053/j.ajkd.2015.09.020
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados